Comparative Pharmacology
Head-to-head clinical analysis: KIMIDESS versus LOESTRIN 21 1 5 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KIMIDESS versus LOESTRIN 21 1 5 30.
KIMIDESS vs LOESTRIN 21 1.5/30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KIMIDESS (ketoconazole) is an imidazole antifungal agent that inhibits the synthesis of ergosterol, a key component of fungal cell membranes, by inhibiting the cytochrome P450 enzyme lanosterol 14-alpha-demethylase.
Combination estrogen-progestin contraceptive: suppresses gonadotropin release, inhibiting ovulation; increases viscosity of cervical mucus, impeding sperm penetration; alters endometrial morphology.
5 mg orally once daily, with or without food.
One tablet (norethindrone acetate 1.5 mg/ethinyl estradiol 30 mcg) orally once daily for 21 consecutive days, followed by 7 days off therapy.
None Documented
None Documented
Terminal elimination half-life is 14 hours (range 10-18 h); supports twice-daily dosing in most patients.
Ethinyl estradiol: ~12-14 h; Norethindrone: ~5-12 h. Steady-state achieved in ~5-10 days.
Renal excretion of unchanged drug accounts for approximately 40% of the administered dose; biliary/fecal elimination accounts for 50%, with the remainder undergoing metabolic clearance.
Primarily hepatic metabolism; ~40-60% renal, 20-30% biliary/fecal.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive